Suppr超能文献

阿尔茨海默病中的神经退行性变与朊病毒蛋白。

The neurodegeneration in Alzheimer disease and the prion protein.

机构信息

Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.

出版信息

Prion. 2013 Jan-Feb;7(1):60-5. doi: 10.4161/pri.23286. Epub 2013 Jan 1.

Abstract

The concept of "prion-like" has been proposed to explain the pathogenic mechanism of the principal neurodegenerative disorders associated with protein misfolding, including Alzheimer disease (AD). Other evidence relates prion protein with AD: the cellular prion protein (PrP(C)) binds β amyloid oligomers, allegedly responsible for the neurodegeneration in AD, mediating their toxic effects. We and others have confirmed the high-affinity binding between β amyloid oligomers and PrP(C), but we were not able to assess the functional consequences of this interaction using behavioral investigations and in vitro tests. This discrepancy rather than being resolved with the classic explanations, differencies in methodological aspects, has been reinforced by new data from different sources. Here we present data obtained with PrP antibody that not interfere with the neurotoxic activity of β amyloid oligomers. Since the potential role of the PrP(C) in the neuronal dysfunction induced by β amyloid oligomers is an important issue, find reasonable explanation of the inconsistent results is needed. Even more important however is the relevance of this interaction in the context of the disease, so as to develop valid therapeutic strategies.

摘要

“朊病毒样”的概念被提出,以解释与蛋白质错误折叠相关的主要神经退行性疾病的发病机制,包括阿尔茨海默病(AD)。其他证据将朊蛋白与 AD 联系起来:细胞朊蛋白(PrP(C))与β淀粉样寡聚体结合,据称β淀粉样寡聚体负责 AD 的神经退行性变,介导其毒性作用。我们和其他人已经证实了β淀粉样寡聚体与 PrP(C)之间的高亲和力结合,但我们无法使用行为研究和体外试验来评估这种相互作用的功能后果。这种差异与其说是通过经典解释来解决的,不如说是由于方法学方面的差异,而是通过来自不同来源的新数据得到了加强。在这里,我们展示了使用 PrP 抗体获得的数据,该抗体不会干扰β淀粉样寡聚体的神经毒性活性。由于 PrP(C)在β淀粉样寡聚体诱导的神经元功能障碍中的潜在作用是一个重要问题,因此需要对不一致的结果找到合理的解释。然而,更重要的是这种相互作用在疾病背景下的相关性,以便开发有效的治疗策略。

相似文献

1
The neurodegeneration in Alzheimer disease and the prion protein.
Prion. 2013 Jan-Feb;7(1):60-5. doi: 10.4161/pri.23286. Epub 2013 Jan 1.
2
Prions, prionoids and pathogenic proteins in Alzheimer disease.
Prion. 2013 Jan-Feb;7(1):55-9. doi: 10.4161/pri.23061. Epub 2012 Dec 3.
3
Alzheimer disease: a tale of two prions.
Prion. 2013 Jan-Feb;7(1):14-9. doi: 10.4161/pri.22118. Epub 2012 Sep 10.
4
High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
Brain. 2014 Mar;137(Pt 3):873-86. doi: 10.1093/brain/awt375. Epub 2014 Feb 10.
5
Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.
Prion. 2013 Jan-Feb;7(1):37-41. doi: 10.4161/pri.22212. Epub 2012 Sep 17.
6
β-amyloid oligomers and prion protein: Fatal attraction?
Prion. 2011 Jan-Mar;5(1):10-5. doi: 10.4161/pri.5.1.14367. Epub 2011 Jan 1.
7
Cellular prion protein and Alzheimer disease: link to oligomeric amyloid-β and neuronal cell death.
Prion. 2013 Mar-Apr;7(2):114-6. doi: 10.4161/pri.22848. Epub 2012 Nov 15.
8
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.
Nature. 2009 Feb 26;457(7233):1128-32. doi: 10.1038/nature07761.
9
Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain.
J Biol Chem. 2011 Apr 29;286(17):15095-105. doi: 10.1074/jbc.M110.199356. Epub 2011 Mar 10.
10
Aβ seeds and prions: How close the fit?
Prion. 2017 Jul 4;11(4):215-225. doi: 10.1080/19336896.2017.1334029. Epub 2017 Jun 28.

引用本文的文献

1
Alzheimer's Disease, Oligomers, and Inflammation.
J Alzheimers Dis. 2018;62(3):1261-1276. doi: 10.3233/JAD-170819.
2
Variable tau accumulation in murine models with abnormal prion protein deposits.
J Neurol Sci. 2017 Dec 15;383:142-150. doi: 10.1016/j.jns.2017.10.040. Epub 2017 Oct 26.
3
Amyloid-beta: a crucial factor in Alzheimer's disease.
Med Princ Pract. 2015;24(1):1-10. doi: 10.1159/000369101. Epub 2014 Nov 27.
4
Single-molecule imaging reveals that small amyloid-β1-42 oligomers interact with the cellular prion protein (PrP(C)).
Chembiochem. 2014 Nov 24;15(17):2515-21. doi: 10.1002/cbic.201402377. Epub 2014 Oct 7.

本文引用的文献

1
Alzheimer's drugs take a new tack.
Nature. 2012 Sep 6;489(7414):13-4. doi: 10.1038/489013a.
2
Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity.
J Biol Chem. 2012 Sep 28;287(40):33104-8. doi: 10.1074/jbc.C112.400614. Epub 2012 Aug 22.
3
Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity.
Br J Pharmacol. 2012 Sep;167(2):383-92. doi: 10.1111/j.1476-5381.2012.01973.x.
4
The P's and Q's of cellular PrP-Aβ interactions.
Prion. 2012 Sep-Oct;6(4):359-63. doi: 10.4161/pri.20675. Epub 2012 Aug 9.
5
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.
Nat Neurosci. 2012 Sep;15(9):1227-35. doi: 10.1038/nn.3178. Epub 2012 Jul 22.
6
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction.
Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006338. doi: 10.1101/cshperspect.a006338.
9
Cell biology. A unifying role for prions in neurodegenerative diseases.
Science. 2012 Jun 22;336(6088):1511-3. doi: 10.1126/science.1222951.
10
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
Nature. 2012 May 2;485(7400):651-5. doi: 10.1038/nature11060.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验